The relationship between concentrations of magnesium and oxidized low density lipoprotein and the activity of platelet activating factor acetylhydrolase in the serum of patients with type 1 diabetes

Magnesium Research

Volumn 23, Issue 2, 2010, Pages 97-104

  Wegner, Małgorzata ^a   Araszkiewicz, Aleksandra ^a   Zozulińska Ziółkiewicz, Dorota ^a   Wierusz Wysocka, Bogna ^a   Pioruńska Mikołajczak, Anna ^a   Pioruńska Stolzmann, Maria ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Inflammation; Magnesium; Oxidative stress; Type 1 diabetes

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; LOW DENSITY LIPOPROTEIN; MAGNESIUM; OXIDIZED LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; BLOOD; CASE CONTROL STUDY; ENZYMOLOGY; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAGNESIUM DEFICIENCY; MALE; STANDARD;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADULT; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; LIPOPROTEINS, LDL; MAGNESIUM; MAGNESIUM DEFICIENCY; MALE; REFERENCE STANDARDS;

EID: 77954436982     PISSN: 09531424     EISSN: 19524021     Source Type: Journal    
DOI: 10.1684/mrh.2010.0207     Document Type: Article

References (35)

1. Vormann J. Magnesium: nutrition and metabolism. Mol Aspects Med 2003; 24: 27-37.
2. Swaminathan R. Magnesium metabolism and its disorders. Clin Biochem Rev 2003; 24: 47-66.
3. Curlier-Garcia JA, Rodriguez-Moran M, Guerrero-Romero F. Hypomagnesaemia and mortality in patients with type 2 diabetes. Magnes Res 2008; 21: 163-6.
4. Bo S, Durazzo M, Guidi S, Carello M, Sacerdote C, Silli B, Rosato R, Casader M, Gentile L, Pagano G. Dietary magnesium and fiber and inflammatory and metabolic indicators in middle-aged subjects from a population- based in middle-aged subjects from a population-based cohort. Am J Clin Nutr 2006; 84: 1062-9.
5. Vasto S, Scapagini G, Bulati M, Candora G. castigilia L, Colonna-Romano C, Lio D, Nuzzo D, Pellicano M, Rizzo C, Ferrara N, Caruso C. Biomarkers of aging. Front Biosci 2010; 1: 392-402.
6. Maier JAM. Low magnesium and atherosclerosis: an evidence-based link. Mol Aspects Med 2003; 24: 137-46.
7. Gowda RM, Khan IA. Magnesium in treatment of acute myocardial infarction. Int J Cardiol 2004; 96: 467-9.
8. Hayaishi-Okano R, Yamasaki Y, Katakani N, Ohtoshi K, Gorogana SJ, Kuroda A, Matsuhisha M, Kosugi K, Nishi-kawa N, Kajimoto Y, Hori M. Elevated C-reactive protein associates with early-stage carotid atherosclerosis in young subjects with type 1 diabetes. Diabetes Care 2002; 25: 1432-8.
9. Phillips M, Cataneo RN, Cheeme T, Greenberg J. Increased breath biomarkers of oxidative stress in diabetes mellitus. Clin Chim Acta 2004; 344: 189-94.
10. Ms D, Henriksen JE. Klitgaard NAH, Blaabjarg O, Thye-Ronn P, Altura BM, Altura BT, Beck-Nielsen H. Effect of moderate improvement in metabolic control on magnesium and lipid concentration in patients with type 1 diabetes. Diabetes Care 1999; 22: 546-54.
11. Atabek ME, Kurtoglu S, Pinagon O, Baykara M. Serum magnesium concentration in type 1 diabetic patients: relation to early atherosclerosis. Diabetes Res Clin Prakt 2006; 72: 42-7.
12. Yajnik CS, Smith RF, Hockaday TD, Ward NI. Fasting plasma magnesium concentrations and glucose disposal in diabetes. Br Med J 1984; 288: 1032-4.
13. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20: 1183-97.
14. Araszkiewicz A, Zozulinska-Ziółkiewicz D, Trepińska M, Wierusz-Wysocka B. Knowledge after five-day teaching program in intensive insulin therapy performed at the onset of type 1 diabetes influences the development of late diabetic complications. Diab Res Clin Pract 2008; 81: 61-7.
15. Zhang L, Albert A, Krzentowski G, Lefebvre PJ. Risk of developing retinopathy in diabetes control and complications trial type 1 diabetic patients with good or poor metabolic control. Diabetes Care 2001; 24: 1275-9.
16. Chauman UPS, Sarker BC. Use of calmagite for the determination of trace of magnesium in biological materials. Anal Biochem 1969; 32: 70-80.
17. Joppsson J, Krobold V, Barr J, Finke A, Hoelzel W, Hoshino T. International federation of clinical chemistry and laboratory medicine (IFCC). Approved IFCC reference method for the measurement of HbA1c in human blood. Clin Chem Lab Med 2002; 40: 78-9.
18. Holvoet P, Macy E, Landeloos M, Jones D, Jenny NS. van de Werf, Tracy RP. Analytical performance and diagnostic accuracy of immunometric assays for the measurement of circulating oxidized LDL. Clin Chem 2006; 52: 760-4.
19. Elamin A, Tuvemo T. Magnesium and insulin- dependent diabetes mellitus. Diabetes Res Clin Pract 1990; 10: 203-9.
20. Sjogren A, Floren CH, Nillson A. Magnesium defi- ciency in IDDM related to level of glycosylated hemoglobin. Diabetes 1986; 35: 459-63.
21. Jessup W, Kritharides L, Stocker R. Lipid oxidation in atherogenesis: an overview. 2004. Biochem Soc Trans 2004; 32: 134-8.
22. Yokoyama S, Gu J, Nishida HJ, Smith TL, Kummerow FA. Combined effects of magnesium deficiency and an atherogenic level of low density lipoprotein on uptake and metabolism of low density lipoprotein by cultured human endothelial cells. II. Electron microscopic data. Magnesium Res 1994; 7: 97-105.
23. Barbagallo M, Belvedere M, Dominiquez LJ. Magne- sium homeostasis and aging. Magnesium Res 2009; 22: 235-46.
24. Pellet L, Milne DB. The influence of magnesium intake on copper indicators in rats deprived of dietary copper. FASEB J 1995; 9: a735.
25. Roy Chowdury SK, Sangle GV, Xie X, Stelmack GL, Halayko AJ, Shen GX. Effects of extensively oxidized low-density lipoprotein on mitochondrial function and reaction oxygen species in porcine aortic endothelial cells. Am J Physiol Endocrinol Metab 2009 [Epub ahead of print]
26. Tuncer S, Karwanki A, Akcil E, Kavas GO, Seckin B, Attay MB. Trace element and magnesium levels and superoxidase dismutase activity in rheumatoid arthri- tis. Biol Trace Elem Res 1999; 68: 137-42.
27. Renkin EM, Curny FE. Endothelial permeability: path- ways and modulations. Ann NY Acid Sci 1982; 401: 248-59.
28. Wegner M, Kasprzak M, Araszkiewicz A, Zozulinska Ziolkiewicz D, Wierusz-Wysocka B, Piorunska Mikołajczak A, Iskra M, Piorunska-Stolzmann M. The evaluation of selected lipoprotein-associated enzymes activity in a group of patients with type 1 diabetes treated with intensive insulin therapy. Clin Chem Lab Med 2009; 47 (Suppl.): 199-200.
29. Ferretti G, Bacchetti D, Busni D, Rabini RA, Curatola G. Protective effect of paraoxonase activity in high- density lipoproteins against erythrocyte membranes peroxidation: a comparison between healthy subjects and type 1 diabetic patients. JCEM 2004; 10: 2957-62.
30. Boemi M, Leviev I, Sirolla C. Serum paraoxonase is reduced in type 1 diabetic patients compared to non- diabetic, first degree relatives: influence on the ability of HDL to protect LDL from oxidation. Atherosclerosis 2001; 155: 229-35.
31. Binder CJ, Chang MK, Show PX, Miller YJ, Hartvigsen K, Dewan A, Witzturn JL. Innate and acquired immunity in atherogenesis. Nat Med 2002; 8: 218-26.
32. Zalewski A, Macphee C. Role of lipoprotein associated phospholipase A2 in atherosclerosis: biology, epidemiology and possible therapeutic target. Atherioscler Thromb Vasc Biol 2005; 25: 923-31.
33. Macphee CH. Lipoprotein-associated phospholipase A2: a potential new risk factor for coronary artery dis- ease and a therapeutic target. Curr Opin Pharmacol 2001; 1: 121-5.
34. Sudhir K. Clinical Review: lipoprotein associated phos pholipase A2, a novel inflammatory biomarker and independent risk predictor for cardiovascular disease. J Clin Endo Metab 2005; 90: 3100-5.
35. Mallat Z, Benessiano J, Simon T, Ederhy S, Sebella-Arquelles C, Cohen A, Huart V, Wareham NJ, Luben R, Khaw KT, Tedgui A, Boekhold SM. Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women. Atherioscler Thromb Vasc Biol 2007; 27: 1177-83.